Bortezomib Intravenous and Quflora
Determining the interaction of Bortezomib Intravenous and Quflora and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using bortezomib together with multivitamin with fluoride. Supplements that contain ascorbic acid, or vitamin C, may reduce the effectiveness of bortezomib in treating your cancer. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Preliminary data suggest that ascorbic acid may diminish the antitumor effects of bortezomib when taken simultaneously. In vitro, ascorbic acid has been shown to inhibit several biologic activities of bortezomib, including induction of apoptosis and G2-M cell cycle arrest and inhibition of proteasome activity, presumably by forming a complex with bortezomib that is both inactive and has poor membrane permeability into cells. A group of investigators showed that plasma from healthy volunteers taking 1 gram of vitamin C per day reduced bortezomib-induced multiple myeloma cell death in vitro. Using a mouse model of human multiple myeloma, they also found that oral vitamin C (40 mg/kg/day) blocked the inhibition of tumor cell growth induced by bortezomib (0.1 mg/kg twice a week for 4 weeks) in immunocompromised mice. The interaction has also been observed in an endometrial carcinoma cell line. In contrast, no effect of ascorbic acid (at plasma concentrations commensurate with human supplemental intake) on bortezomib activity was found in immunocompromised mice bearing CWR22 human prostate xenograft tumors. In light of the fact that vitamin C may protect normal cells from bortezomib toxicity, more studies are needed to further clarify the clinical significance of these findings.
MANAGEMENT: Until more data are available, it may be advisable to avoid taking supplements containing ascorbic acid during bortezomib therapy, or at least on bortezomib treatment days.
- Catley L, Anderson KC "Velcade and vitamin C: too much of a good thing?" Clin Cancer Res 12 (2006): 3-4
- Bannerman B, Xi L, Jones M, et al "Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea." Cancer Chemother Pharmacol 68 (2011): 1145-54
- Zou W, Yue P, Lin N, et al. "Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells." Clin Cancer Res 12 (2006): 273-80
Generic Name: bortezomib
Brand name: Velcade
Synonyms: Bortezomib (Intravenous)
Generic Name: multivitamin with fluoride
Brand name: Floriva, MVC-Fluoride, Poly Vitamin with Fluoride, Poly-Vi-Flor, Quflora, Tri-Vi-Flor, Tri-Vitamin with Fluoride, Vi-Daylin/F, Vi-Daylin/F ADC, Uni Multi with Fluoride, Multi Vita Bets and Fluoride, Tri Vita-Bets with Fluoride, Adeflor M, Fluorabon Basic, Soluvite F, PhluoriVit, TriPhluoriVit, Floriva Plus, Tri-Vite with Fluoride
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bortezomib Intravenous-Quflora FE
- Bortezomib Intravenous-Quflora fe Pediatric Drops
- Bortezomib Intravenous-Quflora Pediatric (Pediatric Multivitamin Chewables with Fluoride)
- Bortezomib Intravenous-Quflora Pediatric (Pediatric Multivitamin Drops with Fluoride)
- Bortezomib Intravenous-Quflora Pediatric Chewable Tablets
- Bortezomib Intravenous-Quflora Pediatric Drops
- Quflora-Bosentan
- Quflora-Bosentan Tablets
- Quflora-Bosentan Tablets for Oral Suspension
- Quflora-Bosulif
- Quflora-Bosutinib
- Quflora-Botox